

Synthesis of Pyrazolo[3,4-*d*]pyrimidines by Intramolecular Cycloaddition of Azahexatrienes

By Fumio Yoneda,* Tomohisa Nagamatsu, and Tetsuya Nagamura, Faculty of Pharmaceutical Sciences, Kumamoto University, Oe-honmachi, Kumamoto 862, Japan
Keitaro Senga, Pharmaceutical Institute, Keio University, Shinanomachi, Shinjuku-ku, Tokyo 160, Japan

Treatment of aldehyde pyrimidin-6-ylhydrazones with aromatic aldehydes (or treatment of 6-hydrazinopyrimidines with aromatic aldehydes in excess) in dimethylformamide under reflux gave 2,3-disubstituted pyrazolo[3,4-*d*]pyrimidines.

PREVIOUS methods for the preparation of pyrazolo[3,4-*d*]pyrimidines¹ involve (a) construction of suitably substituted pyrazole precursors followed by pyrimidine ring closure,^{2,3} (b) condensation-cyclization of 5-substituted 6-hydrazinopyrimidines,^{4,5} and (c) oxidative cyclization of 6-benzylidenehydrazinopyrimidine derivatives.⁶ We now present the experimental details of a new approach to pyrazolo[3,4-*d*]pyrimidines.⁷

Refluxing aldehyde 1,3-dimethyluracil-6-ylhydrazones (1a—g)⁶ with aromatic aldehydes in dimethylformamide gave the corresponding 2,3-disubstituted 5,7-dimethylpyrazolo[3,4-*d*]pyrimidine-4,6(5*H*,7*H*)-diones (2a—k). The structures (2) were confirmed by the benzylic proton signals at δ 5.3—5.5 in the n.m.r. spectra (see Supplementary Publication) and by comparison with authentic samples prepared by benzylation of 3-aryl-5,7-dimethylpyrazolo[3,4-*d*]pyrimidine-4,6(5*H*,7*H*)-diones⁶ with benzyl halides and potassium carbonate in dimethylformamide.[†]

Heating the 6-benzylidenehydrazino-3-methyluracils (3a—c)⁶ with aromatic aldehydes in ethanol gave the 5-benzylidene derivatives (4a—d) possessing a diazahexatriene-type structure. Refluxing the products (4a—d) in dimethylformamide led to the 3-aryl-2-benzyl-5-methylpyrazolo[3,4-*d*]pyrimidine-4,6(5*H*,7*H*)-diones (5a—d). Refluxing of compounds (3a—c) with aromatic aldehydes in dimethylformamide gave the pyrazolo-pyrimidines (5a—d) directly; these products were identified by transformation into compounds (2) by methylation with methyl iodide and potassium carbonate in dimethylformamide.

When acetophenone 1,3-dimethyluracil-6-ylhydrazone (6)⁸ was treated with benzaldehyde in dimethylformamide, 2-(1-methylbenzyl)-5,7-dimethyl-3-phenylpyrazolo[3,4-*d*]pyrimidine-4,6(5*H*,7*H*)-dione (7) was obtained.

Heating the 2-amino-6-benzylidenehydrazino-4-hydroxypyrimidines (8a—d)⁹ with aromatic aldehydes [or heating 2-amino-6-hydrazino-4-hydroxypyrimidine (10)⁹ with an excess of aromatic aldehyde] in dimethyl-

formamide gave the 6-amino-3-aryl-2-benzyl-4-hydroxypyrazolo[3,4-*d*]pyrimidines (9a—d).

EXPERIMENTAL

2,3-Disubstituted 5,7-Dimethylpyrazolo[3,4-*d*]pyrimidine-4,6(5*H*,7*H*)-diones (2a—k). *General Procedure.*—*Method A.* To a solution of an aldehyde 1,3-dimethyluracil-6-ylhydrazone (1) (0.008 mol) in dimethylformamide (50 ml) was added an aromatic aldehyde (0.01 mol). The mixture was refluxed for 7 h, then evaporated to dryness *in vacuo*, and the residue was recrystallized from ethanol to give the corresponding pyrazolo[3,4-*d*]pyrimidine (2a—k) (Table 1).[‡] M.p.s. and yields are indicated below the formulae.

Method B. A mixture of the pyrazolopyrimidine (5) (see later) (0.002 mol), methyl iodide (0.01 mol), and potassium carbonate (0.01 mol) in dimethylformamide (20 ml) was refluxed for 2 h. Inorganic substances were filtered off, the filtrate was evaporated to dryness *in vacuo*, and the residue was diluted with water. Recrystallization of the resulting crystals from ethanol gave the 5,7-dimethylpyrazolo[3,4-*d*]pyrimidinediones, which were identical with the products from method A. Compounds (2a—c) were obtained in 70, 74, and 64% yield, respectively.

5-Benzylidene-6-benzylidenehydrazino-3-methyluracils (4a—d). *General Procedure.*—A mixture of a 6-benzylidenehydrazino-3-methyluracil (3) (0.008 mol) and an aromatic aldehyde (0.01 mol) in ethanol (100—150 ml) was refluxed for 3 h. After cooling, the crystals which separated were filtered off and recrystallized from ethanol. The following compounds were obtained: 5-benzylidene-6-benzylidenehydrazino-3-methyluracil (4a) (88%), m.p. 279° (Found: C, 68.45; H, 4.9; N, 16.75. C₁₆H₁₆N₄O₂ requires C, 68.65; H, 4.85; N, 16.85%); 5-(*p*-chlorobenzylidene)-6-(*p*-chlorobenzylidenehydrazino)-3-methyluracil (4b) (93%), m.p. 298° (Found: C, 56.7; H, 3.7; N, 14.0. C₁₈H₁₄Cl₂N₄O₂ requires C, 56.85; H, 3.5; N, 13.95%); 5-(*p*-methoxybenzylidene)-6-(*p*-methoxybenzylidenehydrazino)-3-methyluracil (4c) (59%), m.p. 267° (Found: C, 63.7; H, 5.55; N, 14.0. C₂₁H₂₂N₄O₄ requires C, 63.95; H, 5.6; N, 14.2%); 5-(*p*-chlorobenzylidene)-6-(*p*-methoxybenzylidenehydrazino)-3-methyluracil (4d) (72%), m.p. 258° (Found: C, 60.8; H, 4.3; N, 14.05. C₂₀H₁₇ClN₄O₃ requires C, 60.55; H, 4.3; N, 14.1%).

⁴ W. Pfeiderer and K. H. Schündehütte, *Annalen*, 1958, **712**, 158.

⁵ Y. Maki, K. Izuta, and M. Suzuki, *Chem. Comm.*, 1971, 1442.

⁶ F. Yoneda and T. Nagamatsu, *Bull. Chem. Soc. Japan*, 1975, **48**, 1484.

⁷ Preliminary report, F. Yoneda, M. Higuchi, and T. Nagamura, *J. Amer. Chem. Soc.*, 1974, **96**, 5607.

⁸ S. Senda and K. Hirota, *Chem. and Pharm. Bull. (Japan)*, 1974, **22**, 1459.

⁹ F. Yoneda, T. Nagamura, and M. Kawamura, *J.C.S. Chem. Comm.*, 1976, 658.

[†] In the benzylation, the isomeric 1-benzylpyrazolo[3,4-*d*]pyrimidine-4,6(5*H*,7*H*)-diones were obtained as minor products.


[‡] Tables 1—3, containing analytical and n.m.r. data, are available as Supplementary Publication No. SUP 21 975 (4 pp.). For details of Supplementary Publications see Notice to Authors No. 7, *J.C.S. Perkin I*, 1976, Index issue.

¹ R. K. Robins, in 'Heterocyclic Compounds,' ed. R. C. Elderfield, vol. 8, Wiley, New York, 1967, pp. 406—421.

² S. M. Mecht and D. Werner, *J.C.S. Perkin I*, 1973, 1903.


³ S. Senda, K. Hirota, and G.-N. Yang, *Chem. and Pharm. Bull. (Japan)*, 1972, **20**, 391, 399.

3-Aryl-2-benzyl-5-methylpyrazolo[3,4-d]pyrimidine-4,6-(5H,7H)-diones (5a—d). *General Procedure.*—*Method A.* A solution of a hydrazone (4) (0.002 mol) in dimethylformamide (20 ml) was refluxed for 3 h. The mixture was evaporated to dryness *in vacuo* and the residue was recrystallized from ethanol to give the pyrazolo[3,4-d]pyrimidine (5) (Table 1). M.p.s and yields are indicated below the formulae.




(1)

- a; R = Ph
 b; R = *p*-ClC₆H₄
 c; R = 3,4-Cl₂C₆H₃
 d; R = *p*-MeO·C₆H₄
 e; R = *p*-Me₂N·C₆H₄
 f; R = MeCH:CH
 g; R = PhCH:CH




(2)

- a; R¹ = R² = Ph (193°C; 80%)
 b; R¹ = R² = *p*-ClC₆H₄ (181°C; 87%)
 c; R¹ = R² = 3,4-Cl₂C₆H₃ (194°C; 85%)
 d; R¹ = R² = *p*-MeO·C₆H₄ (160°C; 84%)
 e; R¹ = R² = *p*-Me₂N·C₆H₄ (258°C; 58%)
 f; R¹ = *p*-MeO·C₆H₄, R² = *p*-ClC₆H₄ (204°C; 68%)
 g; R¹ = *p*-Me₂N·C₆H₄, R² = Ph (150°C; 62%)
 h; R¹ = MeCH:CH, R² = Ph (126°C; 32%)
 i; R¹ = MeCH:CH, R² = *p*-ClC₆H₄ (152°C; 50%)
 j; R¹ = MeCH:CH, R² = 3,4-Cl₂C₆H₃ (194°C; 53%)
 k; R¹ = PhCH:CH, R² = Ph (162°C; 73%)




(3)

- a; R = Ph
 b; R = *p*-ClC₆H₄
 c; R = *p*-MeO·C₆H₄




(4)

- a; R¹ = R² = Ph
 b; R¹ = R² = *p*-ClC₆H₄
 c; R¹ = R² = *p*-MeO·C₆H₄
 d; R¹ = *p*-MeO·C₆H₄, R² = *p*-ClC₆H₄




(5)


- a; R¹ = R² = Ph (231°C; 68%)
 b; R¹ = R² = *p*-ClC₆H₄ (267°C; 87%)
 c; R¹ = R² = *p*-MeO·C₆H₄ (247°C; 78%)
 d; R¹ = *p*-MeO·C₆H₄, R² = *p*-ClC₆H₄ (200°C; 65%)




(6)




(7)



(8)



(9)



(10)

- a; R = Ph
 b; R = *p*-ClC₆H₄
 c; R = 3,4-Cl₂C₆H₃
 d; R = *p*-MeO·C₆H₄

Method B. A mixture of a 6-benzylidenehydrazino-3-methyluracil (3) (0.008 mol) and an aromatic aldehyde (0.01 mol) in dimethylformamide (60—80 ml) was refluxed for 7 h, then evaporated to dryness *in vacuo*, and the residue was recrystallized from ethanol to give (5) in almost the same yields as from method A.

Crotonaldehyde 1,3-Dimethyluracil-6-ylhydrazone (1f).—

To a solution of 1,3-dimethyl-6-hydrazinouracil (6 g, 0.035 mol) in ethanol (180 ml) was added crotonaldehyde (3 g, 0.042 mol), and the mixture was stirred at room temperature for 1 h. The crystals which separated were filtered off, dried, and recrystallized from ethanol to give *prisms* (5.5 g, 70.5%), m.p. 216°, *M*⁺ 222 (Found: C, 54.3; H, 6.45; N, 25.4. C₁₀H₁₄N₄O₂ requires C, 54.05; H, 6.35; N, 25.2%).

Cinnamaldehyde 1,3-Dimethyluracil-6-ylhydrazone (1g).— To a solution of 1,3-dimethyl-6-hydrazinouracil (2 g, 0.012 mol) in ethanol (150 ml) was added cinnamaldehyde (2.1 g, 0.016 mol); treatment as above gave *prisms* (2.84 g, 85%), m.p. 249°, *M*⁺ 312 (Found: C, 63.4; H, 5.55; N, 20.0. C₁₅H₁₆N₄O₂ requires C, 63.35; H, 5.65; N, 19.7%).
 5,7-Dimethyl-2-(1-methylbenzyl)-3-phenylpyrazolo[3,4-d]-

pyrimidine-4,6(5H,7H)-dione (7).—A mixture of acetophenone 1,3-dimethyluracil-6-ylhydrazone (6) (2 g, 0.0074 mol) and benzaldehyde (1.2 g, 0.01 mol) in dimethylformamide (40 ml) was refluxed for 6 h, then evaporated to dryness, and the residue was recrystallized from ethanol to give *granules* (1.55 g, 59%), m.p. 148°, M^+ 360 (Found: C, 69.9; H, 5.65; N, 15.3. $C_{21}H_{20}N_4O_2$ requires C 70.0; H, 5.6; N, 15.55%).

6-Amino-3-aryl-2-benzyl-4-hydroxypyrazolo[3,4-d]-pyrimidines (9a—d). *General Procedure.*—*Method A.* A mixture of 2-amino-6-hydrazino-4-hydroxypyrimidine (10) (0.01 mol) and an aromatic aldehyde (0.024 mol) in dimethyl-

formamide (50 ml) was refluxed for 5 h. After cooling, the crystals precipitated were filtered off and recrystallized from dimethylformamide [yields 60—90% (Table 2)], m.p. $< 360^\circ$. The structures (9) were confirmed by the benzylic proton n.m.r. signals at δ 5.7—5.5. (Table 3 in Supplementary Publication).

Method B. Compounds (9a—d) were also prepared by the condensation of 2-amino-6-benzylidenehydrazino-4-hydroxypyrimidines (8a—d) and aromatic aldehydes in dimethylformamide in similar yields.

[6/1200 Received, 21st June, 1976]